Want to see IMNN full AI Analyst Report?
IMNN Stock Chart & Stats
$3.10
-$0.06(-6.43%)
At close: 4:00 PM EST
$3.10
-$0.06(-6.43%)
Day’s Range― - ―
52-Week Range$1.51 - $8.19
Previous CloseN/A
Volume151.93K
Average Volume (3M)180.69K
Market Cap
$6.35M
Enterprise Value$10.90
Total Cash (Recent Filing)$4.79M
Total Debt (Recent Filing)$911.75K
Price to Earnings (P/E)―
Beta-0.72
Next Earnings
Aug 06, 2026EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.86
Shares Outstanding4,202,118
10 Day Avg. Volume410,974
30 Day Avg. Volume180,689
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.00Price Target Upside254.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.28
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase II Overall Survival BenefitA ~14.7-month median OS improvement in OVATION II is a durable signal of meaningful clinical activity versus SOC. Such a robust survival advantage increases the probability that the program will be viewed favorably by investigators, partners and regulators, underpinning long-term strategic value.
Phase III Enrollment Momentum And Site EngagementActive site enthusiasm and early enrollment above assumptions materially reduce operational execution risk for a large pivotal trial. Sustained investigator engagement shortens recruitment timelines, preserves statistical power, and strengthens prospects for timely interim analyses and regulatory discussions.
Non-dilutive Structured $10M FinancingA $10M structured financing that avoids heavy equity dilution provides immediate runway to fund enrollment while limiting shareholder dilution. This financing structure and collateral mechanics offer durable capital flexibility to advance OVATION III and demonstrate access to alternative funding sources.
Bears Say
Long Timeline To Pivotal Readout (last Patient Q1 2029)A prolonged enrollment/readout timetable extends time to regulatory clarity and commercial value realization. Extended timelines increase cumulative cash needs, expose the program to evolving SOC changes, and prolong execution risk, making near-term financing and partner arrangements more critical and uncertain.
Negative Operating Cash Flow And Funding DependencyOngoing negative operating and free cash flow, despite some burn reduction, signals structural funding risk. Continued dependence on external financings raises dilution or covenant risks and constrains strategic optionality, potentially impacting trial pacing, partnerships, or commercialization planning over months.
Near-zero Revenue And Persistent LossesSustained lack of product revenue and recurring material operating losses mean the company will remain funding-dependent for the foreseeable 2–6 month horizon. Persistent negative results also limit reinvestment capacity and increase strategic reliance on partnerships or external capital to reach commercialization inflection points.
Imunon News
IMNN FAQ
What was Imunon, Inc.’s price range in the past 12 months?
Imunon, Inc. lowest stock price was $1.51 and its highest was $8.19 in the past 12 months.
What is Imunon, Inc.’s market cap?
Imunon, Inc.’s market cap is $6.35M.
When is Imunon, Inc.’s upcoming earnings report date?
Imunon, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 10 days.
How were Imunon, Inc.’s earnings last quarter?
Currently, no data Available
Is Imunon, Inc. overvalued?
According to Wall Street analysts Imunon, Inc.’s price is currently Undervalued.
Does Imunon, Inc. pay dividends?
Imunon, Inc. does not currently pay dividends.
What is Imunon, Inc.’s EPS estimate?
Imunon, Inc.’s EPS estimate is -0.87.
How many shares outstanding does Imunon, Inc. have?
Imunon, Inc. has 4,202,118 shares outstanding.
What happened to Imunon, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Imunon, Inc.?
Currently, no hedge funds are holding shares in IMNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Imunon, Inc.
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
IMNN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong, potentially transformative clinical data (a ~14.7-month median OS benefit from OVATION II), clear enrollment momentum and favorable safety/translation signals, supported by an active plan to present additional data and to pursue investor-friendly financing. Counterbalancing these positives are a challenging capital market, a materially prolonged Phase III enrollment and readout timeline (last patient expected Q1 2029), and increased near-term cash burn driven by trial start-up costs. Management has outlined a restructuring and creative financing approach to conserve cash and limit dilution, and investor interest appears constructive. Overall, the clinical progress and enrollment momentum materially support upside potential, while financing and timeline risks remain meaningful near-term headwinds.View all IMNN earnings summariesIMNN Stock 12 Month Forecast
Average Price Target
$11.00
▲(254.84% Upside)
Technical Analysis
Ownership Overview
5.63% Insiders
0.94% Mutual Funds
<0.01% Other Institutional Investors
92.31% Public Companies and
Individual Investors